109 related articles for article (PubMed ID: 9499437)
1. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study.
Hallak R; Mueller J; Lotter O; Gansauge S; Gansauge F; el-Deen Jumma M; Montenarh M; Safi F; Beger H
Int J Oncol; 1998 Apr; 12(4):785-91. PubMed ID: 9499437
[TBL] [Abstract][Full Text] [Related]
2. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis.
Leahy DT; Salman R; Mulcahy H; Sheahan K; O'Donoghue DP; Parfrey NA
J Pathol; 1996 Dec; 180(4):364-70. PubMed ID: 9014855
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation found to be a significant prognostic indicator in distal colorectal cancer.
Okubo R; Masuda H; Nemoto N
Oncol Rep; 2001; 8(3):509-14. PubMed ID: 11295071
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Br J Cancer; 1995 May; 71(5):1013-7. PubMed ID: 7734292
[TBL] [Abstract][Full Text] [Related]
7. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
8. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis.
de Witte HH; Foekens JA; Lennerstrand J; Smid M; Look MP; Klijn JG; Benraad TJ; Berns EM
Int J Cancer; 1996 Apr; 69(2):125-30. PubMed ID: 8608980
[TBL] [Abstract][Full Text] [Related]
10. p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry.
Curtin K; Slattery ML; Holubkov R; Edwards S; Holden JA; Samowitz WS
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):380-6. PubMed ID: 15536342
[TBL] [Abstract][Full Text] [Related]
11. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas.
Dix B; Robbins P; Carrello S; House A; Iacopetta B
Br J Cancer; 1994 Oct; 70(4):585-90. PubMed ID: 7917901
[TBL] [Abstract][Full Text] [Related]
12. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
13. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
14. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
15. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
[TBL] [Abstract][Full Text] [Related]
16. Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer.
Caldes T; Iniesta P; Vega FJ; de Juan C; Lopez JA; Diaz-Rubio E; Fernandez C; Cerdan J; Balibrea JL; Benito M
Oncology; 1998; 55(3):249-57. PubMed ID: 9560058
[TBL] [Abstract][Full Text] [Related]
17. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue.
Broll R; Duchrow M; Oevermann E; Wellm C; Schwandner O; Schimmelpenning H; Roblick UJ; Bruch HP; Windhövel U
Int J Colorectal Dis; 2001 Feb; 16(1):22-7. PubMed ID: 11317693
[TBL] [Abstract][Full Text] [Related]
18. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas.
Soong R; Robbins PD; Dix BR; Grieu F; Lim B; Knowles S; Williams KE; Turbett GR; House AK; Iacopetta BJ
Hum Pathol; 1996 Oct; 27(10):1050-5. PubMed ID: 8892589
[TBL] [Abstract][Full Text] [Related]
19. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
20. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors.
Norberg T; Lennerstrand J; Inganäs M; Bergh J
Int J Cancer; 1998 Aug; 79(4):376-83. PubMed ID: 9699530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
